| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Keun-Ah Cheon, Young Hoon Ryu, Young-Kee Kim, Kee Namkoong, Chan-Hyung Kim, Jong Doo Le. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. European journal of nuclear medicine and molecular imaging. vol 30. issue 2. 2003-09-26. PMID:12552351. |
our findings support the complex dysregulation of the dopaminergic neurotransmitter system in children with adhd. |
2003-09-26 |
2023-08-12 |
Not clear |
| Cristina Bäckman, Zhi Bing You, Thomas Perlmann, Barry J Hoffe. Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamine. Behavioural brain research. vol 143. issue 1. 2003-09-09. PMID:12842300. |
gene targeting experiments, in which both alleles of the nurr1 gene were deleted, have shown that this molecule plays an essential role in the development of midbrain dopaminergic neurons, as shown by the loss of dopaminergic markers and the neurotransmitter dopamine (da) in the ventral mesencephalon of nurr1 null mutant mice. |
2003-09-09 |
2023-08-12 |
mouse |
| Hung Fang, Joanne Chartier, Caroline Sodja, Angele Desbois, Maria Ribecco-Lutkiewicz, P Roy Walker, Marianna Sikorsk. Transcriptional activation of the human brain-derived neurotrophic factor gene promoter III by dopamine signaling in NT2/N neurons. The Journal of biological chemistry. vol 278. issue 29. 2003-08-27. PMID:12738784. |
this ability of da to regulate the expression of the bdnf survival factor has a profound significance for the nigrostriatal pathway, because it indicates the existence of a feedback loop between the neutrophin, which promotes both the maturation and survival of dopaminergic neurons, and the neurotransmitter, which the mature neurons ultimately produce and release. |
2003-08-27 |
2023-08-12 |
human |
| M Hansenne, E Pinto, G Scantamburlo, A Couvreur, J Reggers, S Fuchs, W Pitchot, M Anssea. Mismatch negativity is not correlated with neuroendocrine indicators of catecholaminergic activity in healthy subjects. Human psychopharmacology. vol 18. issue 3. 2003-08-22. PMID:12672172. |
however, given the complexity of the central neurotransmitter systems, these results cannot be considered as definitive evidence against a relationship between dopaminergic and noradrenergic activity and the mmn. |
2003-08-22 |
2023-08-12 |
human |
| b' Horst H Simon, Lavinia Bhatt, Daniel Gherbassi, Paola Sgad\\xc3\\xb3, Lavinia Alber\\xc3\\xa. Midbrain dopaminergic neurons: determination of their developmental fate by transcription factors. Annals of the New York Academy of Sciences. vol 991. 2003-08-04. PMID:12846972.' |
this requirement is specific to the midbrain dopaminergic neurons, since other populations of the same neurotransmitter phenotype develop normally in absence of the gene. |
2003-08-04 |
2023-08-12 |
human |
| M D Julian, A B Martin, B Cuellar, F Rodriguez De Fonseca, M Navarro, R Moratalla, L M Garcia-Segur. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience. vol 119. issue 1. 2003-07-28. PMID:12763090. |
our data suggest that the majority of the striatal cb1 receptors are located presynaptically on inhibitory gabaergic terminals, in a position to modulate neurotransmitter release and influence the activity of substantia nigra dopaminergic neurons. |
2003-07-28 |
2023-08-12 |
rat |
| M Gassen, I Lamensdorf, T Armony, J P M Finberg, M B H Youdi. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. Journal of neural transmission (Vienna, Austria : 1996). vol 110. issue 2. 2003-07-11. PMID:12589576. |
work in models of monoamine depletion and neuroleptic induced catalepsy in rats suggests a interaction of flupirtine with the dopaminergic neurotransmitter system as well. |
2003-07-11 |
2023-08-12 |
mouse |
| Päivi Tuomainen, Anton Patsenka, Petri Hyytiä, Vladimir Grinevich, Kalervo Kiianma. Extracellular levels of dopamine in the nucleus accumbens in AA and ANA rats after reverse microdialysis of ethanol into the nucleus accumbens or ventral tegmental area. Alcohol (Fayetteville, N.Y.). vol 29. issue 2. 2003-07-11. PMID:12782253. |
the findings support the suggestion that the increase in the extracellular level of dopamine in the nucleus accumbens after systemic administration of ethanol may involve other sites on dopamine neurons or even different neurotransmitter systems, rather than the action of ethanol at the mesolimbic dopaminergic terminals. |
2003-07-11 |
2023-08-12 |
rat |
| Mario F Wullimann, Thomas Muelle. Expression of Zash-1a in the postembryonic zebrafish brain allows comparison to mouse Mash1 domains. Brain research. Gene expression patterns. vol 1. issue 3-4. 2003-07-03. PMID:12638130. |
subpallial gabaergic interneurons versus pallial glutamatergic projection neurons, or dopaminergic neurons versus other neurotransmitter phenotypes). |
2003-07-03 |
2023-08-12 |
mouse |
| J Kirschner, G H Moll, U M Fietzek, H Heinrich, V Mall, S Berweck, F Heinen, A Rothenberge. Methylphenidate enhances both intracortical inhibition and facilitation in healthy adults. Pharmacopsychiatry. vol 36. issue 2. 2003-07-01. PMID:12734766. |
enhancement of both of these tms parameters was unexpected and suggests that mph exerts its action on the motor cortex not only through the dopaminergic neurotransmitter system. |
2003-07-01 |
2023-08-12 |
Not clear |
| Jeffery D Stekete. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants. Brain research. Brain research reviews. vol 41. issue 2-3. 2003-06-10. PMID:12663081. |
these pyramidal neurons are modulated by numerous neurotransmitter systems, including gamma-aminobutyric acidergic interneurons and dopaminergic, noradrenergic, serotonergic, glutamatergic, cholinergic and peptidergic afferents. |
2003-06-10 |
2023-08-12 |
Not clear |
| J-C Seznec, J-P Lépine, A Pélissol. [Dimensional personality assessment of the members of the French junior national team of road cycling]. L'Encephale. vol 29. issue 1. 2003-05-14. PMID:12640324. |
these personality traits are hypothetically related to underlying neurotransmitter systems (especially ns to dopaminergic function and ha to serotonergic function). |
2003-05-14 |
2023-08-12 |
human |
| Andreas Reif, Klaus-Peter Lesc. Toward a molecular architecture of personality. Behavioural brain research. vol 139. issue 1-2. 2003-05-02. PMID:12642172. |
in recent years, molecular genetics has begun to identify specific genes coding in particular for components of the serotonergic and dopaminergic neurotransmitter systems representing quantitative trait loci (qtls) for behavioral traits. |
2003-05-02 |
2023-08-12 |
Not clear |
| J Ludovic Croxfor. Therapeutic potential of cannabinoids in CNS disease. CNS drugs. vol 17. issue 3. 2003-03-31. PMID:12617697. |
evidence suggests that cannabinoids may prove useful in parkinson's disease by inhibiting the excitotoxic neurotransmitter glutamate and counteracting oxidative damage to dopaminergic neurons. |
2003-03-31 |
2023-08-12 |
Not clear |
| Channi Kumar, Ronan J McIvor, Tony Davies, Nigel Brown, Andrew Papadopoulos, Angelika Wieck, Stuart A Checkley, Iain C Campbell, Maureen N Mark. Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. The Journal of clinical psychiatry. vol 64. issue 2. 2003-03-26. PMID:12633118. |
these relapses may be triggered by the postdelivery fall in circulating estrogen through alteration of central neurotransmitter (especially dopaminergic) systems. |
2003-03-26 |
2023-08-12 |
Not clear |
| Brian M Ross, Robert J Brooks, Margaret Lee, Kathryn S Kalasinsky, Shawn P Vorce, Mary Seeman, Paul J Fletcher, Sylvie D Turenn. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. European journal of pharmacology. vol 450. issue 2. 2003-03-24. PMID:12206852. |
their apparent ability to antagonise hypoactivity without generalised dopaminergic stimulation suggests that other, possibly multiple, neurotransmitter systems may be involved. |
2003-03-24 |
2023-08-12 |
rat |
| Manolis Markianos, John Hatzimanolis, Lefteris Lykoura. Relationship between prolactin responses to ECT and dopaminergic and serotonergic responsivity in depressed patients. European archives of psychiatry and clinical neuroscience. vol 252. issue 4. 2003-02-24. PMID:12242577. |
the prolactin (prl) increases in plasma, induced by the electrical stimulus during electroconvulsive therapy (ect), is a consistent finding that can be studied in order to obtain information about its actions on the brain neurotransmitter systems, the most probable candidates being the serotonergic and the dopaminergic system. |
2003-02-24 |
2023-08-12 |
human |
| Pippa S Loupe, Jonna D Bredemeier, Stephen R Schroeder, Richard E Tesse. Dopamine re-uptake inhibitor GBR-12909 induction of aberrant behaviors in animal models of dopamine dysfunction. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. vol 20. issue 3-5. 2002-12-17. PMID:12175869. |
brain imaging studies have found that several of these individuals have abnormalities in their dopaminergic neurotransmitter systems that are thought to be responsible in part, for the development of these behaviors. |
2002-12-17 |
2023-08-12 |
rat |
| Jean-Denis Troadec, Marc Marien, Sophie Mourlevat, Thomas Debeir, Merle Ruberg, Francis Colpaert, Patrick P Miche. Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Molecular pharmacology. vol 62. issue 5. 2002-11-12. PMID:12391266. |
activation of the mitogen-activated protein kinase (erk(1/2)) signaling pathway by cyclic amp potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. |
2002-11-12 |
2023-08-12 |
Not clear |
| T Mülle. Non-dopaminergic drug treatment of Parkinson's disease. Expert opinion on pharmacotherapy. vol 2. issue 4. 2002-11-06. PMID:11336607. |
several lines of evidence suggest that substitution of the dopaminergic striatal deficit only represents one important aspect of the treatment of parkinson's disease (pd) because neurotransmitter systems other than the dopaminergic one also degenerate and aggravate parkinsonian motor, vegetative and cognitive symptoms. |
2002-11-06 |
2023-08-12 |
Not clear |